Benitec Announces FDA Type C Meeting Feedback for BB-301 Pivotal Study
The FDA has requested additional data, including OPMD natural history study results, but confirmed the pivotal trial remains on track to begin enrolling patients in mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed